Tandem Diabetes Care, Inc. Q4 2025 Earnings Call Summary

Core Insights - The company surpassed $1 billion in annual sales in 2025, driven by record fourth-quarter pump shipments and double-digit growth in both U.S. and international markets [1] Business Model Transition - Management is fundamentally reshaping the business model by transitioning to a 'pay-as-you-go' (PayGo) reimbursement structure in the pharmacy channel to reduce patient out-of-pocket barriers [1] - The shift to pharmacy is expected to double the lifetime revenue per patient while streamlining the prescription process for healthcare providers and improving data visibility for payers [1] International Growth - International growth was supported by record sales despite the operational complexity of transitioning to direct commercial operations in the U.K., Switzerland, and Austria [1] Operational Efficiency - Operational efficiency improved significantly, with Q4 gross margins reaching a record 58% due to manufacturing efficiencies and a reduction in non-cash stock-based compensation [1] Market Expansion - The company expanded its addressable market in 2025 by launching Control-IQ+ for type 2 diabetes and integrating with FreeStyle Libre 3 Plus for t:slim, with plans to launch Dexcom's 15-day sensor integration in the second quarter of 2026 [1]